



⑪ Publication number : **0 414 847 B1**

⑫ **EUROPEAN PATENT SPECIFICATION**

④⑤ Date of publication of patent specification :  
**08.09.93 Bulletin 93/36**

⑤① Int. Cl.<sup>5</sup> : **A61K 31/44, C07D 401/12**

②① Application number : **90902854.0**

②② Date of filing : **02.02.90**

⑧⑥ International application number :  
**PCT/SE90/00070**

⑧⑦ International publication number :  
**WO 90/09175 23.08.90 Gazette 90/20**

⑤④ **USE OF OMEPRAZOLE AS AN ANTIMICROBIAL AGENT.**

③⑦ Priority : **09.02.89 JP 130311/89**

④③ Date of publication of application :  
**06.03.91 Bulletin 91/10**

④⑤ Publication of the grant of the patent :  
**08.09.93 Bulletin 93/36**

⑧④ Designated Contracting States :  
**AT BE CH DE DK ES FR GB IT LI LU NL SE**

⑤⑥ References cited :  
**EP-A- 0 045 200**  
**SE-A- 8 600 742**  
**The Lancet, June 4, 1983, p. 1273**  
**The Lancet, June 16, 1984, p. 1312-1314**  
**Microbios Letters 25, 1984, p. 83-88**  
**Sledman's Medical Dictionary, 25th Ed. p. 295,**  
**326, 430, 516**  
**Medicinsk Terminologi Lexicon, p. 423**

⑦③ Proprietor : **Aktiebolaget Hässle**  
**Kärragatan 5**  
**S-431 83 Mölndal (SE)**

⑦② Inventor : **TOMOI, Masaaki 3-5-65-1214,**  
**Nishi-Iwata**  
**Higashi-Osaka City**  
**Osaka 530 (JP)**  
Inventor : **IKEDA, Yoshifumi 914-2,**  
**Oaza-Nakasoi**  
**Nakatsu City**  
**Osaka 870 (JP)**  
Inventor : **YOKOTA, Yoshiko 25-8,**  
**Wakazono-cho**  
**Ibaraki-shi**  
**Osaka-fu 530 (JP)**

⑦④ Representative : **Linderöth, Margareta et al**  
**AB Astra Patent Department**  
**S-151 85 Södertälje (SE)**

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**EP 0 414 847 B1**

## Description

### Field of the Invention

5 The present invention relates to the new use of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole (generic name: omeprazole) or a salt thereof as an antimicrobial agent and more particularly as an antimicrobial agent, which is particularly active against gram-negative bacteria.

### Background of the Invention

10 In view of the abuse or unscrupulous use of antimicrobial drugs in the treatment of infectious diseases or for other purposes and the consequent emergence of drug-resistant strains, increased incidence of microbial substitution due to disturbance of the bacterial flora, changes in profile of infectious diseases, etc., there has been a constant demand for the development of new antimicrobial agents.

15 This application is especially directed to the treatment of infections caused by *Campylobacter pylori*. *Campylobacter pylori* is a gram-negative spirilliform bacterium which colonises deeply in the gastric mucosa. Treatment with commonly used antibiotics has given insufficient effect.

### Prior art

20 Omeprazole and its pharmaceutically acceptable salts, which are used in accordance with the invention, are known compounds, e.g. from EP 5129 and EP 124495 and can be produced by known processes, for example by the process described in Japanese Patent Application No. 34956/1985.

### Outline of the invention

25 The intensive research undertaken by the inventors of the present invention for accomplishing the above-mentioned object revealed surprisingly that 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole (generic name: omeprazole) and pharmaceutically acceptable salts thereof, which are known to have gastric antisecretory activity known to be an antiulcer drug have excellent antimicrobial activity as well.

Heretofore, it has never been known that omeprazole or any compound analogous thereto has antimicrobial activity.

35 Predicated on the above finding, the present invention relates to an antimicrobial agent containing omeprazole or a salt thereof as an active ingredient.

The salt of omeprazole is virtually optional in kind but is preferably a pharmaceutically acceptable salt. Examples of such salts include inorganic salts, such as alkali metal salts, e.g. sodium salt, potassium salt etc., alkaline earth metal salts, e.g. calcium salt, magnesium salt etc., ammonium salt, organic salts such as organic amine salts, e.g. trimethylamine salt, triethylamine salt, pyridine salt, procaine acid, picoline salt, dicyclohexylamine salt, N,N-dibenzylethylenediamine salt, N-methylglucine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)methane salt, phenylethylbenzylamine salt, dibenzylethylenediamine salt.

40 The antimicrobial agent according to the present invention is particularly active against gram-negative bacteria, especially microaerophilic bacteria, *inter alia* bacteria of the genus *Campylobacter* represented by *C. pylori*, and can be effectively utilized for the prevention and treatment of infectious diseases due to such bacteria in mammalian animals including man, cattle, horse, dog, mouse and rat, in the control and inhibition of environmental pollution, or as a disinfectant.

45 The antimicrobial agent according to the present invention can be made available in a pharmaceutical formulation comprising one or more active ingredients selected from the group consisting of omeprazole and salts thereof or in a formulation containing optional substances as additives (for example, a carrier).

50 For the treatment or prevention of bacterial infections, for instance, the antimicrobial agent of the invention is generally administered in the form of a pharmaceutical preparation containing omeprazole as such (i.e. the free base) or a salt thereof as an active ingredient in combination with a pharmaceutically acceptable carrier by the oral, rectal or parenteral route. The carrier mentioned above may be a solid, semi-solid or liquid diluent or a capsule. Compatible dosage forms include various types of tablets, capsules, granules, powders, oral liquids, injections and so on. The proportions of the active ingredient in the total composition is generally 0.1 to 100 weight percent and preferably 0.1 to 95 weight percent. In the case of an injectable preparation, the range of 0.1 to 20 weight percent is particularly preferred. In the case of a preparation for oral administration, the preferred proportion is 2 to 50 weight percent.

In the manufacture of a pharmaceutical preparation for oral administration, the active ingredient can be formulated with a solid particulate carrier such as lactose, sucrose, sorbitol, mannitol, starch, amylopectin, a cellulose derivative or gelatin, and a lubricating agent such as magnesium stearate, calcium stearate or polyethylene glycol wax may be further incorporated. The resulting composition is then compressed into tablets.

5 Coated tablets or dragees can be manufactured by coating the core tablets, thus prepared, with a thick sugar solution containing gum arabic, gelatin, talc, titanium dioxide, etc. or a lacquer prepared using a volatile organic solvent or solvent mixture.

Soft gelatin capsules can be manufactured by filling a composition comprising the active ingredient and a known vegetable oil into capsules. Hard gelatin capsules can be manufactured by filling into capsules the granules or pellets each comprising the active ingredient and a solid particulate carrier such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, a cellulose derivative or gelatin.

Preparations for rectal administration are preferably suppositories containing the active ingredient and a neutral oleaginous base, gelatin capsules for rectal administration which contain the active ingredient and a vegetal oil or paraffin oil, and rectal ointments.

15 Liquid preparations for oral administration can be syrups or suspensions, typically a solution containing 0.2 to 20 weight percent of the active ingredient with the balance being a mixture of sucrose with ethanol, water, glycerol and/or propylene glycol. Optionally, these preparations may additionally contain colors, corrigents, saccharin and, as a thickener, carboxymethylcellulose.

20 Injections can be manufactured in the form of aqueous solutions, typically an aqueous solution containing a pharmaceutically acceptable water-soluble salt of the active ingredient preferably in a concentration of 0.1 to 10 weight percent. These preparations may further contain a stabilizer and/or a buffer and may be provided in ampules containing various unit doses.

The dosage of omeprazole or a salt thereof depends on individual needs (for example, the patient's condition, body weight, age, sex, etc.) as well as on the method of administration. Generally speaking, the oral dosage may range from 1 to 400 mg as active ingredient per day per adult human and the intravenous dosage may range from 1 to 200 mg per day per adult human, and each may be administered in one to a few divided doses.

#### 30 Pharmacological data

##### Experiment 1

The in vitro antimicrobial activity of the active ingredient of the present invention was assayed by the following agar plate dilution method.

35 A loopful ( $10^7$  cells/ml) of the test strain cultured in Brucella Broth containing 5% of horse serum under 10% carbon dioxide gas for 2 days was inoculated onto Brucella Agar containing 5% horse lysed blood. This medium contained a varying concentration of omeprazole. The inoculated media were incubated at 37°C under 10% carbon dioxide gas for 2 days and the minimal inhibitory concentration (MIC) was determined. The result is set forth in Table 1.

Table 1

45	Test organism	MIC ( $\mu\text{g/ml}$ )
	Campylobacter	
50	pylori 8005	0.39

#### 55 EXAMPLES

The following examples are intended to illustrate the antimicrobial agent of the invention in further detail and should by no means be constructed as limiting the scope of the invention.

## Example 1 (25 mg tablets)

Omeprazole 250 g  
 Lactose 175.8 g  
 5 Corn starch 169.7 g

The above ingredients are mixed and wetted with 10% gelatin solution, and the wet mixture is sieved through a 12-mesh screen and pulverized. The resulting powder is dried and magnesium stearate is added. This mixture is then compressed into tablets each containing 25 mg of omeprazole.

## 10 Example 2 (capsules)

Omeprazole 93.5 weight %  
 Carboxymethylcellulose calcium 3.7 weight %  
 Magnesium stearate 1.9 weight %  
 15 Light silicic anhydride 0.9 weight %  
 The above ingredients are mixed thoroughly and filled into capsules.

## Example 3 (capsules)

20 Omeprazole sodium 93.5 weight %  
 Carboxymethylcellulose calcium 3.7 weight %  
 Magnesium stearate 1.9 weight %  
 Light silicic anhydride 0.9 weight %  
 The above ingredients are mixed thoroughly and filled into capsules in the conventional manner.

25

## Example 4 (injection)

Omeprazole sodium 40 mg  
 Sterile water to a final volume of 10 ml

30 The above ingredients are aseptically filled into separate vials to provide an injectable preparation.

## Example 5 (capsules)

Pellets without an intermediate layer

35

I - Pulverized mannitol	16150 g
Dehydrated lactose	800 g
Hydroxypropylcellulose	600 g
40 - Microcrystalline cellulose	400 g
II - Omeprazole	2000 g
Sodium laurylsulfate	40 g
45 Disodium hydrogen phosphate	80 g
- Distilled water for injection	4400 g

50 The dry ingredients (I) are mechanically pre-mixed and, then, a granulated liquid component (II) containing omeprazole is added. The resulting mass is kneaded and moistened to a suitable viscosity. The wet mass is processed by means of an extruder to give spherical pellets which are then dried and screened for size selection.

55